G. De Manzoni et al., Clinical significance of mutator phenotype and chromosome 17p and 18q allelic loss in gastric cancer, BR J SURG, 88(3), 2001, pp. 419-425
Background: Tumour stage is the only reliable prognostic factor for gastric
cancer. The molecular anomalies involved in this process have the potentia
l to serve as additional prognostic markers.
Methods: Forty-four gastric cancers, treated by surgery alone, have been an
alysed for chromosome 17p and 18q allelic loss and for the presence of micr
osatellite instability (MSI), using microsatellite markers and DNA from par
affin-embedded tumours.
Results: Eight cancers showed a MSI-positive (MSI+) phenotype. Among the 36
MSI-negative cancers, chromosome 17p and 18q allelic losses were found in
22 of 34 and 19 of 33 informative cases respectively. Multivariate survival
analysis indicated MSI status to be an independent prognostic factor along
with the tumour stage. MSI+ cancers were associated with longer patient su
rvival, whereas MSI-negative cancers had a significantly poorer prognosis (
P = 0.007), with a median actuarial survival of 24 months.
Conclusion: MSI status is an independent prognostic factor among gastric ca
ncers at the same stage. Chromosome 17p and 18q status added no additional
prognostic information to that of tumour stage. The combined use of tumour
stage and MSI status may help in deciding whether patients with advanced ga
stric cancer require additional therapy other than surgery alone.